Brief: Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
28/02/2024 13:34
Feb 28 (Reuters) - Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS ANNOUNCES CLEARANCE OF IND FOR SPR206
TO
TREAT MDR GRAM-NEGATIVE BACTERIAL INFECTIONS
Source text for Eikon: ID:nGNX5ryDKq
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)